表紙
市場調査レポート

B型肝炎:世界の治験レビュー

Hepatitis B Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 217846
出版日 ページ情報 英文 134 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
B型肝炎:世界の治験レビュー Hepatitis B Global Clinical Trials Review, H2, 2014
出版日: 2014年11月28日 ページ情報: 英文 134 Pages
概要

B型肝炎は、B型肝炎ウィルス(HBV)によって感染した肝臓が炎症を起こした疾患です。これは世界でも重大な健康問題の一つであり、ウィルス性肝炎の中でも最も深刻な種類です。子供の方が慢性感染症のリスクが高く、B型肝炎ウイルス(HBV)以外にもアルコールのような毒素によって発生します。また、感染者の血液、精液、膣液、他の体液との接触によっても感染が拡大します。

当レポートでは、B型肝炎に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んで、お届けします。

イントロダクション

  • B型肝炎
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 上位5ヶ国における治験件数; 中東/アフリカ地域
    • 上位5ヶ国における治験件数; 中南米

G7諸国における治験件数: B型肝炎治験件数の感染症治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数: B型肝炎治験件数の感染症治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

未完了の治験 B型肝炎

一定期間に採用された被験者数

スポンサーの種類別の治験件数

有望なスポンサー

治験主要参加企業 - B型肝炎治療薬

有望な薬剤

  • 最新治験ニュース: B型肝炎

治験のプロファイル

  • 代表的な企業の治験の概要
    • GlaxoSmithKline plc
    • Gilead Sciences, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Sanofi
    • Bukwang Pharm.Co., Ltd.
    • Dynavax Technologies Corporation
    • LG Life Sciences, Ltd.
  • 代表的な研究機関/病院の治験の概要
    • National Taiwan University Hospital
    • The National Institute of Diabetes and Digestive and Kidney Diseases
    • The National Institute of Allergy and Infectious Diseases
    • Sun Yat-sen University
    • Third Affiliated Hospital of Sun Yat-sen University
    • Yonsei University
    • The Foundation for Liver Research
    • Chinese University of Hong Kong
    • The University of Hong Kong
    • French National Agency for Research on AIDS and Viral Hepatitis

5大治験プロファイル

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC2439CTIDB

GlobalData's clinical trial report, "Hepatitis B Global Clinical Trials Review, H2, 2014" provides data on the Hepatitis B clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis B. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis B. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Hepatitis B
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Hepatitis B
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Hepatitis B Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Hepatitis B
    • Nov 10, 2014: TetraLogic Pharmaceuticals Announces Results Of Preclinical Studies In Hepatitis B
    • Nov 10, 2014: Novira Therapeutics Announces Presentation of Phase 1a Safety and Pharmacokinetic Data for NVR 3-778
    • Nov 10, 2014: Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B
    • Oct 21, 2014: Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic Hepatitis B and Delta
    • Oct 15, 2014: Tekmira Presents Results Of Preclinical Studies With Hepatitis B Therapeutic
    • Oct 09, 2014: Tekmira to Present HBV Pre-Clinical Data at Meeting of the Oligonucleotide Therapeutics Society
    • Oct 08, 2014: Arrowhead to Present ARC-520 Phase 2a Data in Late-Breaking Session at AASLD Liver Meeting 2014
    • Oct 07, 2014: REPLICor to Present Updated Clinical Trial Data of REP-9-AC at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
    • Oct 01, 2014: REPLICor announces initiation of its Phase II clinical trial with REP 2139-Ca in combination with Pegasys in patients with hepatitis B / hepatitis D co-infection
    • Sep 25, 2014: Radiant Research/Clinical Research Advantage Enrolls More Than 8,000 Subjects for Hepatitis B Vaccine Study
    • Sep 22, 2014: Dynavax Completes Enrollment of Phase 3 Study of HEPLISAV-B
    • Sep 04, 2014: Novira Therapeutics Announces Successful Completion of Phase 1a Clinical Study of NVR-1221 and Commencement of Phase 1b Clinical Studies
    • Aug 27, 2014: TetraLogic Pharmaceuticals to Present Data From Pre-Clinical Studies With Hepatitis B at the 2014 International Meeting on Molecular Biology of Hepatitis B Viruses
    • Aug 27, 2014: Green Cross Initiates Phase II Trial of Investigational Recombinant Hepatitis B Immune Globulin
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • Gilead Sciences, Inc.
      • Clinical Trial Overview of Gilead Sciences, Inc.
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • Bristol-Myers Squibb Company
      • Clinical Trial Overview of Bristol-Myers Squibb Company
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Sanofi
      • Clinical Trial Overview of Sanofi
      • Bukwang Pharm.Co., Ltd.
      • Clinical Trial Overview of Bukwang Pharm.Co., Ltd.
      • Dynavax Technologies Corporation
      • Clinical Trial Overview of Dynavax Technologies Corporation
      • LG Life Sciences, Ltd.
      • Clinical Trial Overview of LG Life Sciences, Ltd.
    • Clinical Trial Overview of Top Institutes / Government
      • National Taiwan University Hospital
      • Clinical Trial Overview of National Taiwan University Hospital
      • The National Institute of Diabetes and Digestive and Kidney Diseases
      • Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases
      • The National Institute of Allergy and Infectious Diseases
      • Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases
      • Sun Yat-sen University
      • Clinical Trial Overview of Sun Yat-sen University
      • Third Affiliated Hospital of Sun Yat-sen University
      • Clinical Trial Overview of Third Affiliated Hospital of Sun Yat-sen University
      • Yonsei University
      • Clinical Trial Overview of Yonsei University
      • The Foundation for Liver Research
      • Clinical Trial Overview of The Foundation for Liver Research
      • Chinese University of Hong Kong
      • Clinical Trial Overview of Chinese University of Hong Kong
      • The University of Hong Kong
      • Clinical Trial Overview of The University of Hong Kong
      • French National Agency for Research on AIDS and Viral Hepatitis
      • Clinical Trial Overview of French National Agency for Research on AIDS and Viral Hepatitis
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Hepatitis B Therapeutics, Global, Clinical Trials by Region, 2014*
  • Hepatitis B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Hepatitis B Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Hepatitis B to Infectious Disease Clinical Trials, G7 Countries (%), 2014*
  • Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Hepatitis B to Infectious Disease Clinical Trials, E7 Countries (%), 2014*
  • Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Hepatitis B Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Hepatitis B Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Hepatitis B Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Hepatitis B Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Hepatitis B Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Hepatitis B Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Bukwang Pharm.Co., Ltd., 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Dynavax Technologies Corporation, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by LG Life Sciences, Ltd., 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Yat-sen University, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Third Affiliated Hospital of Sun Yat-sen University, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Yonsei University, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by The Foundation for Liver Research, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Chinese University of Hong Kong, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Hong Kong, 2014*
  • Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by French National Agency for Research on AIDS and Viral Hepatitis, 2014*

List of Figures

  • Hepatitis B Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Hepatitis B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Hepatitis B Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Hepatitis B Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Hepatitis B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014*
  • Hepatitis B Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Hepatitis B to Infectious Disease Clinical Trials, G7 Countries (%), 2014*
  • Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Hepatitis B to Infectious Disease Clinical Trials, E7 Countries (%), 2014*
  • Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Hepatitis B Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Hepatitis B Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Hepatitis B Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Hepatitis B Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Hepatitis B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top